FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008442675> ?p ?o ?g. }

• W2008442675 endingPage "521" @default.
• W2008442675 startingPage "510" @default.
• W2008442675 abstract "Background: Cisplatin is effective in the treatment of several cancers but is a known ototoxin resulting in shifts to hearing sensitivity in up to 50–60% of patients. Cisplatin-induced hearing shifts tend to occur first within an octave of a patient’s high frequency hearing limit, termed the sensitive range for ototoxicity (SRO), and progress to lower frequencies. While it is currently not possible to know which patients will experience ototoxicity without testing their hearing directly, monitoring the SRO provides an early indication of damage. A tool to help forecast susceptibility to ototoxic-induced changes in the SRO in advance of each chemotherapy treatment visit may prove useful for ototoxicity monitoring efforts, patient counseling, and therapeutic planning. Purpose: This project was designed to (1) establish pretreatment risk curves that quantify the probability that a new patient will suffer hearing loss within the SRO during treatment with cisplatin and (2) evaluate the accuracy of these predictions in an independent sample of Veterans receiving cisplatin for the treatment of cancer. Study Sample: Two study samples were used. The Developmental sample contained 23 subjects while the Validation sample consisted of 12 subjects. Data Collection and Analysis: Risk curve predictions for SRO threshold shifts following cisplatin exposure were developed using a Developmental sample comprised of data from a total of 155 treatment visits obtained in 45 ears of 23 Veterans. Pure-tone thresholds were obtained within each subject’s SRO at each treatment visit and compared with baseline measures. The risk of incurring an SRO shift was statistically modeled as a function of factors related to chemotherapy treatment (cisplatin dose, radiation treatment, doublet medication) and patient status (age, pre-exposure hearing, cancer location and stage). The model was reduced so that only statistically significant variables were included. Receiver-operating characteristic (ROC) curve analyses were then used to determine the accuracy of the risk curve predictions in an independent Validation sample of observations from over 62 treatment visits obtained in 24 ears of 12 Veterans. Results: Only cumulative cisplatin dose and pre-exposure hearing were found to be significantly related to the risk for hearing shift. The dose-ototoxicity risk curve predictions developed from the Developmental sample yielded area under the ROC curve accuracy estimates of 0.85 when applied to an independent Validation sample. Conclusions: Cumulative cisplatin dose in combination with pre-exposure hearing provides an indication of whether hearing will shift in the SRO in advance of cisplatin administration. The validated dose-ototoxicity risk curves described herein can be used before and during treatment to anticipate hearing loss. While having such a tool would not replace serial hearing testing, it would be of great benefit to an ototoxicity monitoring program. It would promote relevant pretreatment counseling. Furthermore, for those found to be at risk of SRO shifts within the speech frequencies, the oncology treatment plan could incorporate anticipated dosing adjustments that could stave off the impact that ototoxicity might bring." @default.
• W2008442675 created "2016-06-24" @default.
• W2008442675 creator A5011498316 @default.
• W2008442675 creator A5036219137 @default.
• W2008442675 creator A5038896159 @default.
• W2008442675 creator A5051760854 @default.
• W2008442675 creator A5064255812 @default.
• W2008442675 creator A5064317096 @default.
• W2008442675 date "2012-07-01" @default.
• W2008442675 modified "2023-09-28" @default.
• W2008442675 title "Development and Validation of a Cisplatin Dose-Ototoxicity Model" @default.
• W2008442675 cites W1492075988 @default.
• W2008442675 cites W192940008 @default.
• W2008442675 cites W1965804065 @default.
• W2008442675 cites W1975642122 @default.
• W2008442675 cites W1977258390 @default.
• W2008442675 cites W1981133182 @default.
• W2008442675 cites W1983019584 @default.
• W2008442675 cites W1986305277 @default.
• W2008442675 cites W1994327500 @default.
• W2008442675 cites W1996271706 @default.
• W2008442675 cites W1998147719 @default.
• W2008442675 cites W2000697304 @default.
• W2008442675 cites W2003937881 @default.
• W2008442675 cites W2005941853 @default.
• W2008442675 cites W2007956298 @default.
• W2008442675 cites W2011874831 @default.
• W2008442675 cites W2024375371 @default.
• W2008442675 cites W2028297759 @default.
• W2008442675 cites W2042196995 @default.
• W2008442675 cites W2048348507 @default.
• W2008442675 cites W2049970371 @default.
• W2008442675 cites W2050292508 @default.
• W2008442675 cites W2057331388 @default.
• W2008442675 cites W2059998155 @default.
• W2008442675 cites W2061113629 @default.
• W2008442675 cites W2065114172 @default.
• W2008442675 cites W2066063421 @default.
• W2008442675 cites W2071582175 @default.
• W2008442675 cites W2076111661 @default.
• W2008442675 cites W2086517190 @default.
• W2008442675 cites W2089244804 @default.
• W2008442675 cites W2134807418 @default.
• W2008442675 cites W2152788129 @default.
• W2008442675 cites W2166035874 @default.
• W2008442675 cites W2328903697 @default.
• W2008442675 cites W2329180009 @default.
• W2008442675 cites W2340018179 @default.
• W2008442675 cites W2409900372 @default.
• W2008442675 cites W2412906761 @default.
• W2008442675 cites W2417674086 @default.
• W2008442675 doi "https://doi.org/10.3766/jaaa.23.7.3" @default.
• W2008442675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5549622" @default.
• W2008442675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22992258" @default.
• W2008442675 hasPublicationYear "2012" @default.
• W2008442675 type Work @default.
• W2008442675 sameAs 2008442675 @default.
• W2008442675 citedByCount "26" @default.
• W2008442675 countsByYear W20084426752012 @default.
• W2008442675 countsByYear W20084426752013 @default.
• W2008442675 countsByYear W20084426752014 @default.
• W2008442675 countsByYear W20084426752015 @default.
• W2008442675 countsByYear W20084426752016 @default.
• W2008442675 countsByYear W20084426752017 @default.
• W2008442675 countsByYear W20084426752018 @default.
• W2008442675 countsByYear W20084426752019 @default.
• W2008442675 countsByYear W20084426752020 @default.
• W2008442675 countsByYear W20084426752021 @default.
• W2008442675 countsByYear W20084426752022 @default.
• W2008442675 countsByYear W20084426752023 @default.
• W2008442675 crossrefType "journal-article" @default.
• W2008442675 hasAuthorship W2008442675A5011498316 @default.
• W2008442675 hasAuthorship W2008442675A5036219137 @default.
• W2008442675 hasAuthorship W2008442675A5038896159 @default.
• W2008442675 hasAuthorship W2008442675A5051760854 @default.
• W2008442675 hasAuthorship W2008442675A5064255812 @default.
• W2008442675 hasAuthorship W2008442675A5064317096 @default.
• W2008442675 hasBestOaLocation W20084426752 @default.
• W2008442675 hasConcept C105795698 @default.
• W2008442675 hasConcept C121332964 @default.
• W2008442675 hasConcept C126322002 @default.
• W2008442675 hasConcept C129848803 @default.
• W2008442675 hasConcept C24890656 @default.
• W2008442675 hasConcept C2776694085 @default.
• W2008442675 hasConcept C2778239845 @default.
• W2008442675 hasConcept C2778534666 @default.
• W2008442675 hasConcept C2780493683 @default.
• W2008442675 hasConcept C33923547 @default.
• W2008442675 hasConcept C44249647 @default.
• W2008442675 hasConcept C548259974 @default.
• W2008442675 hasConcept C71924100 @default.
• W2008442675 hasConcept C85841341 @default.
• W2008442675 hasConceptScore W2008442675C105795698 @default.
• W2008442675 hasConceptScore W2008442675C121332964 @default.
• W2008442675 hasConceptScore W2008442675C126322002 @default.
• W2008442675 hasConceptScore W2008442675C129848803 @default.
• W2008442675 hasConceptScore W2008442675C24890656 @default.
• W2008442675 hasConceptScore W2008442675C2776694085 @default.

• next